Maine HIE offers real-time predictive analytics

 

Maine’s health information exchange (HIE), HealthInfoNet, is now offering providers analytic and predictive tools to study market share, clinical performance, population health and patient risk in real-time. 

The HIE’s clinical data repository contains records for nearly 1.3 million state residents, which derive from 32 of Maine’s 36 acute care hospitals and 326 ambulatory locations--including primary and specialty care practices and long-term care facilities. “This rich dataset allows for much more timely assessment of patient risk that can be leveraged for clinical treatment and care coordination before high-cost events occur,” according to a press release.

So far, five state organizations have entered contracts with HealthInfoNet to utilize this service—including two large hospitals and Maine’s Pioneer ACO. St. Joseph Healthcare in Bangor was the first organization to use the new tools and is currently studying whether their use has resulted in a reduction in hospital readmissions, according to HealthInfoNet CEO Devore Culver.

“They dove right into the tools and have been a great partner to help us expand and improve our service. They took a team approach to testing the new tool, setting up super users in the hospital and the outpatient setting. And they are seeing results,” Culver said in a statement.

In addition, HealthInfoNet is partnering with vendor HBI Solutions to help HIEs outside of Maine utilize these tools. “HealthInfoNet has been a leader in the HIE space for sometime and feel we have a lot to offer other HIE organizations as they set up similar services,” said Culver. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.